Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | BRAF V47_M438del BRAF V600E |
Therapy | Cetuximab + Irinotecan + Vemurafenib |
Indication/Tumor Type | colon adenocarcinoma |
Response Type | predicted - resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V47_M438del BRAF V600E | colon adenocarcinoma | predicted - resistant | Cetuximab + Irinotecan + Vemurafenib | Case Reports/Case Series | Actionable | In a clinical case study, BRAF V47_M438del (reported as deletion of exons 2-10) was identified in the post-progression biopsy of a patient with colon adenocarcinoma harboring BRAF V600E, who previously responded to the combination of Captosar (irinotecan), Erbitux (cetuximab), and Zelboraf (vemurafenib) (PMID: 32669268). | 32669268 |
PubMed Id | Reference Title | Details |
---|---|---|
(32669268) | An amino-terminal BRAF deletion accounting for acquired resistance to RAF/EGFR inhibition in colorectal cancer. | Full reference... |